Bültmann & Gerriets
The Emergence of Drugs which Block Calcium Entry
von Ronald D. Smith, Stanley R. Jolly, John R. Regan, Peter S. Wolf
Verlag: Springer Berlin Heidelberg
Reihe: Progress in Clinical Biochemistry and Medicine Nr. 6
Hardcover
ISBN: 978-3-642-73230-0
Auflage: Softcover reprint of the original 1st ed. 1988
Erschienen am 16.12.2011
Sprache: Englisch
Format: 244 mm [H] x 170 mm [B] x 10 mm [T]
Gewicht: 302 Gramm
Umfang: 168 Seiten

Preis: 106,99 €
keine Versandkosten (Inland)


Dieser Titel wird erst bei Bestellung gedruckt. Eintreffen bei uns daher ca. am 12. November.

Der Versand innerhalb der Stadt erfolgt in Regel am gleichen Tag.
Der Versand nach außerhalb dauert mit Post/DHL meistens 1-2 Tage.

106,99 €
merken
klimaneutral
Der Verlag produziert nach eigener Angabe noch nicht klimaneutral bzw. kompensiert die CO2-Emissionen aus der Produktion nicht. Daher übernehmen wir diese Kompensation durch finanzielle Förderung entsprechender Projekte. Mehr Details finden Sie in unserer Klimabilanz.
Klappentext
Inhaltsverzeichnis

Calcium Entry Blockers (CEBs) are a new class of drugs which have been pushing back the frontiers of science and medicine for almost two decades. This report reviews some of the wealth of chemical, biological and clinical data describing the discovery and development of these compounds. The scientific importance, therapeutic benefit and marketing potential of these compounds have caused an explosion of scientific literature describing their effects in many preclinical and clinical settings. The definitional characteristics of these compounds suggest a certain predictability of their biological profile but their therapeutic usefulness varies widely dependent upon their physical properties, net hemodynamic effects, duration of action and incidence of side effects. CEBs appear uniquely suited to the treatment of the underlying complexity of cardiovascular disease. The CEBs of the future may live up to the expectations of pathophysiologically based therapeutics and allow the heart and blood vessels to outlive the cells which they support. The development of CEBs is an evolving story of epic proportions and represents the cooperative efforts of individuals in all areas of science.



Abstracts.- 1 Introduction: Calcium Entry Blockers (CEBs).- 1.1 History of Calcium Entry Blocker New Drug Discovery.- 1.2 Nomenclature and Classification.- 1.3 Definitional Characteristics.- 1.4 Screening Philosophy.- 1.5 Methodological Notes for Screening Vascular Effects.- 2 Current Calcium Entry Blocker.- 2.1 Status of CEB New Drug Discovery.- 2.2 Additional Sites of Action.- 3 Preclinical Pharmacology.- 3.1 Vasodilator Effects of CEBs.- 3.2 Antihypertensive Effects of CEBs.- 3.3 CEB Effects on Myocardial Rate and Rhythm.- 3.4 Anti-Ischemic/Myocardial Protective Effects of CEBs.- 3.5 Cytoprotective Effects of CEBs in Hepatic Injury.- 3.6 Cytoprotective Actions of CEBs in Models of Cerebral Ischemic Injury.- 3.7 Effects of CEBs on Airway Smooth Muscle and Mast Cell Mediator Release.- 3.8 CEBs in Atherosclerosis.- 3.9 Effects of CEBs on Platelet Aggregation.- 3.10 Effects of CEBs on Red Blood CElls.- 3.11 CEBs and Neutrophil Function.- 3.12 Endocrine Effects of CEBs.- 4 Therapeutic Indications.- 4.1 Angina Pectoris.- 4.2 Arterial Hypertension.- 4.3 Vascular Disease.- 4.4 Congestive Heart Failure.- 4.5 Myocardial Arrhythmias.- 4.6 Asthma.- 4.7 Other Therapeutic Indications.- 5 Adverse Effects.- 6 Perspectives: CEB New Drug Discovery.- 7 Acknowledgement.- 8 References.- Author Index Volumes 1-6.


weitere Titel der Reihe